OBJECTIVES: The main factor influencing the costs development of medical devices for compression therapy of venous insufficiency (MDCT) are new diagnostic and therapeutic possibilities, expanding the range of medical devices with new functions and a subgroup compression stockings containing silver. MDCT are reimbursed from Health insurance funds, but there is a presence of a high patient co-payment.

METHODS: The target of the work was to analyse the data from paid databases of Slovak authority National Center for Health Information that collects the outputs of provided health care. The data were focused on totally or partly reimbursed medical devices (MD) from public health insurance funds The selected group was medical devices for compression therapy of venous insufficiency. The most recent data were from 1.1. 2009 - 31.12. 2013. It was used basic and advanced statistic processing by Microsoft Excel.

RESULTS: Referring to the National Center for Health Information, in the observed period, the share of MDCT on total consumption of MD stagnated (MDCT/MD=0.09%; MDCT/MD=0.12%; ΔMDCT/MD_{=0.04%). The total quantitative consumption MDCT increased (Δ=51 760pcs/66.72%; max=129 339pcs; min=77 579pcs; AVG=98 910pcs; Mean=95 987pcs; SD=19 398). The share of MDCT on total reimbursement of MD stagnated (MDCT/MD=1.39%; MDCT/MD=1.53%; ΔMDCT/MD=0.14%). The total reimbursement in the observed period increased (Δ=608 756€/34.09%; max=2 394 665€; min=1 785 909€; AVG=2 015 533€; Mean=1 983 142€; SD=19 398). The share of MDCT on the patient supplements of MD slightly increased (MDCT/MD=3.74%; MDCT/MD=5.42%; ΔMDCT/MD=1.68%). The total patient supplements increased (Δ=165 257€/141.27%; max=282 248€; min=116 991€; AVG=181 612€; Mean=160 686€; SD=67 547).  CONCLUSIONS: MDCT have supplements for patients that greatly exceed the reimbursement from the resources of public health insurance. Legislative changes in the list of categorized medical devices brought gradual increase patient´s co-payment for MDCT.}